Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs BYVALSON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
FDA-approved for the treatment of hypertension, heart failure (NYHA class II-IV), and to reduce cardiovascular mortality in stable post-myocardial infarction patients with left ventricular dysfunction or failure.,Off-label uses include diabetic nephropathy, prevention of atrial fibrillation recurrence, and migraine prophylaxis.
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
160 mg orally once daily.
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
Valsartan is primarily metabolized by CYP2C9 and minimally by CYP3A4. It undergoes glucuronidation via UGT1A3, UGT1A9, and UGT2B7. The major metabolite is inactive.
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
95% bound primarily to albumin
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
Vd 8-10 L/kg; suggests extensive extravascular distribution
Intravenous: 100% (only route of administration).
Oral: 50% (range 40-60%); food reduces peak concentration but not AUC
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
No dosage adjustment required for GFR ≥30 m L/min; not recommended for GFR <30 m L/min.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
Contraindicated in severe hepatic impairment (Child-Pugh class C); no adjustment for mild to moderate impairment (Child-Pugh A or B).
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
Safety and efficacy not established in pediatric patients.
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
No specific dose adjustment recommended; initiate cautiously due to potential for decreased renal function.
None.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal malformations, oligohydramnios, and neonatal renal failure. Discontinue as soon as pregnancy is detected.
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Hypotension in volume- or salt-depleted patients,Hyperkalemia, especially with renal impairment, diabetes, or concomitant potassium-sparing diuretics,Renal function impairment, including acute renal failure,Angioedema (rare),Use caution in severe aortic stenosis,Avoid concomitant use with aliskiren in diabetic patients
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
Pregnancy (absolute),History of angioedema from any ARB or ACE inhibitor,Concomitant use with aliskiren in diabetic patients (absolute),Severe hepatic impairment (Child-Pugh class C) (relative)
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium chloride, as BYVALSON can increase potassium levels.
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypotension. Risk is highest in the second and third trimesters; first-trimester exposure may also increase risk of congenital malformations.
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
No data on Byvalson (valsartan/nebivolol) in breast milk. Valsartan is excreted in rat milk; unknown in humans. Nebivolol is likely excreted in human milk. Due to potential for adverse effects in nursing infants (hypotension, bradycardia), breastfeeding is not recommended. M/P ratio not established.
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
Byvalson is contraindicated in pregnancy; no dose adjustment is recommended. Alternative antihypertensives with established safety profiles should be used. If exposure occurs, discontinue immediately and manage with appropriate therapy.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
BYVALSON (sacubitril/valsartan) is a first-in-class ARNI approved for heart failure with reduced ejection fraction (HFr EF). Monitor blood pressure and renal function closely upon initiation, especially in patients on high-dose ACE inhibitors or ARBs. Avoid use with ACE inhibitors within 36 hours due to risk of angioedema. May cause hypotension, hyperkalemia, and renal impairment. Titrate every 2-4 weeks to target dose of 97/103 mg BID as tolerated.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
Do not take within 36 hours of any ACE inhibitor medication.,Take BYVALSON twice daily with or without food.,Monitor blood pressure regularly; report dizziness or fainting.,Avoid salt substitutes containing potassium.,Seek medical help immediately if you experience swelling of the face, lips, or throat.,Stay hydrated but do not use potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs BYVALSON, answered by our medical review team.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. BYVALSON is a Angiotensin II Receptor Blocker that works by Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and BYVALSON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. The standard adult dose of BYVALSON is: 160 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and BYVALSON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. BYVALSON is classified as Category C. Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypoten. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.